NOVEMBER/DECEMBER

Vol 9, No 6 CME Pretest

This Journal provides 4 hours of Category 1 Continuing Medical Education

Complimentary CME Credits

Physicians can earn 4 credit hours of Category 1 for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions in the posttest at the end of this issue. Complete instructions are given on the posttest pages. Successfully answering 30 or more questions will earn 4 credit hours.

Educational Objectives

After reading this issue of Cancer Control, clinicians will be expected to:

• discuss the hereditary risk factors for breast cancer and consider using ductal lavage for assessment of breast cancer risk,

• recognize the significance of amenorrhea and the effects on fertility from adjuvant therapy for breast cancer, and

• utilize new knowledge on aromatase inhibitors, bisphosphonates, and trastuzumab to prescribe optimal breast cancer care.

This program was planned in accordance with ACCME Essentials.

Release Date: December 1, 2002
Expiration Date: December 1, 2003

1. One in 40 women of Ashkenazi descent carries one of three specific BRCA1 or BRCA2 mutations. Women in which of the following countries also carry similar genetic alterations?

a. Holland and Iceland
b. Denmark and Poland
c. Scotland and France
d. Germany and Wales

2. Which one of the following drugs is probably the most significant cause of amenorrhea in premenopausal women?

a. doxorubicin
b. 5-fluorouracil
c. methotrexate
d. cyclophosphamide

3. Cardiac effects from trastuzumab are most likely to occur with:

a. high cumulative dose
b. using a q 3 week schedule
c. prior anthracycline
d. young age at start of treatment